CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) has formed a strategic alliance with Weill Cornell Medicine to become the exclusive partner for the development and commercialization of UroMap, a urine-based gene-expression test aimed at detecting acute cellular rejection in kidney transplant recipients. UroMap demonstrates high accuracy in identifying rejection episodes and may predict future occurrences. This collaboration enhances CareDx's portfolio of kidney transplant solutions, including AlloSure® and KidneyCare™. The exclusive rights for UroMap were secured through a license agreement with Cornell University.

Positive

• Exclusive partnership with Weill Cornell Medicine to develop UroMap.
• UroMap technology shows high accuracy in identifying acute rejection episodes.
• Enhances CareDx's existing kidney transplant solutions portfolio.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic alliance with Weill Cornell Medicine that makes CareDx the exclusive development and commercialization partner of UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

CareDx is collaborating with Weill Cornell Medicine on a multi-year research collaboration with exclusive rights to bring UroMap to patients. UroMap – developed by Dr. Manikkam Suthanthiran, a pioneer in molecular diagnostics and Chief of Nephrology, Hypertension and Transplantation Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and his collaborators at Weill Cornell Medicine – is an extensively studied technology including a study published in the New England Journal of Medicine. The NEJM study concluded that the UroMap technology is able to distinguish acute rejection episodes with high accuracy, and may predict future development of an acute rejection episode.

Adding UroMap to CareDx’s suite of kidney transplant solutions, which includes AlloSure® and KidneyCare™, may potentially provide healthcare professionals a comprehensive view of immune and injury status of the transplanted kidney. CareDx’s solutions enable cutting-edge patient management and support optimizing immunosuppression.

“UroMap provides early detection and quantification of clinically relevant cellular rejection,” said Dr. Suthanthiran, who is also the named inventor on the patent for the urine gene expression technology. “We are hopeful that this test will benefit kidney transplant patients.”

“We are delighted to announce this collaboration with Weill Cornell Medicine to help bring UroMap’s rapid allograft rejection detection capabilities to our industry-leading suite of transplant care solutions,” said Peter Maag, CEO of CareDx. “We continue our commitment to fund research and drive innovation for transplant patient care.”

CareDx has obtained the exclusive rights to the UroMap technology through an exclusive license agreement with Cornell University, which was negotiated with Cornell University’s technology transfer office, Center for Technology Licensing at Cornell University (CTL).

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com 

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com 

FAQ

What is the recent partnership between CareDx and Weill Cornell Medicine?

CareDx has formed a strategic alliance with Weill Cornell Medicine to exclusively develop and commercialize UroMap, a urine-based test for kidney transplant rejection.

What is UroMap and how does it benefit kidney transplant patients?

UroMap is a urine-based gene-expression test that detects acute cellular rejection in kidney transplant recipients, potentially improving patient management.

What are the main advantages of the UroMap technology?

UroMap offers high accuracy in identifying acute rejection episodes and may predict future rejection events, thus enhancing transplant care.

When was the partnership between CareDx and Weill Cornell Medicine announced?

The partnership was announced on May 5, 2020.

What is the stock symbol of CareDx?

The stock symbol for CareDx is CDNA.